Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (201-210 of 377) with videos related to

Pageof 38
Sort By:
Virchows Archiv : an International Journal of Pathology|February 2, 2018
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigmGiuseppe Pelosi, Fabrizio Bianchi, Elisa Dama, et al.
Expert Opinion on Drug Discovery|October 4, 2013
Advances towards the design and development of personalized non-small-cell lung cancer drug therapySabrina Vari, Sara Pilotto, Marcello Maugeri-Saccà, et al.
Journal of Thoracic Disease|August 14, 2025
Short-term results of salvage surgery after immune and target therapies in non-small cell lung cancerMarco Chiappetta, Carolina Sassorossi, Filippo Lococo, et al.
Pathologica|October 8, 2024
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockadeAlessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2019
Pembrolizumab as first-line treatment for metastatic uveal melanomaErnesto Rossi, Monica Maria Pagliara, Daniela Orteschi, et al.
Frontiers in Oncology|September 27, 2021
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus <i>nab</i>-paclitaxel for Advanced Pancreatic AdenocarcinomaIlaria Trestini, Luisa Carbognin, Umberto Peretti, et al.
Heliyon|December 17, 2024
Simultaneous care provision to patients with small cell lung cancer in Lazio region: Practical recommendations of a multidisciplinary groupSabrina Mariotti, Gabriele Minuti, Lorenza Landi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non-Small Cell Lung CancerMaurice Pérol, Benjamin J Solomon, Koichi Goto, et al.
Anticancer Research|February 27, 2022
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?Chiara Ciccarese, Roberto Iacovelli, Sebastiano Buti, et al.
Cancers|July 31, 2019
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?Ernesto Rossi, Giovanni Schinzari, Ilaria Grazia Zizzari, et al.
Pageof 38

Showing results (201-210 of 377) with videos related to

Sort By:
Pageof 38
Virchows Archiv : an International Journal of Pathology|February 2, 2018
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigmGiuseppe Pelosi, Fabrizio Bianchi, Elisa Dama, et al.
Expert Opinion on Drug Discovery|October 4, 2013
Advances towards the design and development of personalized non-small-cell lung cancer drug therapySabrina Vari, Sara Pilotto, Marcello Maugeri-Saccà, et al.
Journal of Thoracic Disease|August 14, 2025
Short-term results of salvage surgery after immune and target therapies in non-small cell lung cancerMarco Chiappetta, Carolina Sassorossi, Filippo Lococo, et al.
Pathologica|October 8, 2024
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockadeAlessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2019
Pembrolizumab as first-line treatment for metastatic uveal melanomaErnesto Rossi, Monica Maria Pagliara, Daniela Orteschi, et al.
Frontiers in Oncology|September 27, 2021
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus <i>nab</i>-paclitaxel for Advanced Pancreatic AdenocarcinomaIlaria Trestini, Luisa Carbognin, Umberto Peretti, et al.
Heliyon|December 17, 2024
Simultaneous care provision to patients with small cell lung cancer in Lazio region: Practical recommendations of a multidisciplinary groupSabrina Mariotti, Gabriele Minuti, Lorenza Landi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non-Small Cell Lung CancerMaurice Pérol, Benjamin J Solomon, Koichi Goto, et al.
Anticancer Research|February 27, 2022
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?Chiara Ciccarese, Roberto Iacovelli, Sebastiano Buti, et al.
Cancers|July 31, 2019
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?Ernesto Rossi, Giovanni Schinzari, Ilaria Grazia Zizzari, et al.
Pageof 38